MSD grabs Eyebiotech Ltd for US$1.3bn upfront
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
ADVERTISEMENT
New Search
If you are not happy with the results below please do another search
52 search results for: MSD
Curve Therapeutics in US$1.7bn deal with MSD
/in Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
BIOncoTech Therapeutics and MSD combine cancer drugs
/in Latest NewsMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Noxxon/MSD start testing of immunoncologic combo
/in Latest NewsLast December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
BerGenBio plans IPO and partners with MSD
/in Latest NewsNorwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Mercks PD-1 inhibitor pembrolizumab in lung cancer patients.
Proteros inks US$167m oncology pact with MSD
/in Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.
WuXi Biologics Sells Irish Vaccine Site to Merck for $500m
/in Latest NewsWuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
BIOTECH SUMMIT AUSTRIA: Seed to succeed
/in AssociationsThe BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.
ImmunOs Therapeutics AG raises US$11m in Series C financing
/in Latest NewsSwiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
Klineo raises €2m to speed up access to cancer trials
/in Latest NewsParis-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.
`